Prime Therapeutics Expanding Formulary Exclusion Program In 2018
The NetResults formulary contributed to a 0.2% decline in overall drug spending by the pharmacy benefit manager's commercial clients in 2017, according to Prime Therapeutics' Drug Trend report.
You may also be interested in...
Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017
Express Scripts' annual drug trend report highlights impact of key follow-on launches, and its own management solutions programs, in limiting the growth in overall drug spending for commercial plans to 1.5%; forecast calls for double-digit growth in inflammatory category to continue at least the next three years until biosimilar savings kick in.
CVS 2018 Formulary: Outcomes-Based Contracts In Oncology, Obesity, COPD
And for diabetes, Jardiance is out and Invokana is in; CVS formulary update includes far fewer exclusions than previous years and reinstates coverage for several drugs, signaling more muted approach to management.
PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule
Bill aims to lower patient costs in part by engaging the US Federal Trade Commission to shed light on pharmacy benefit manager transactions with health plans, manufacturers and pharmacies.